체외막산소화요법(ECMO) 시장 : 세계 예측(2026-2032년)

The Extracorporeal Membrane Oxygenation Therapy Market is projected to grow by USD 7.08 billion at a CAGR of 12.09% by 2032.

Extracorporeal Membrane Oxygenation Therapy: Executive Overview

Extracorporeal membrane oxygenation (ECMO) is an advanced life-support therapy that temporarily supports cardiac, respiratory, or combined cardiopulmonary function when conventional treatment is insufficient. Venovenous ECMO primarily supports severe respiratory failure, while venoarterial ECMO supports circulatory failure and cardiogenic shock. Its use requires specialized equipment, multidisciplinary expertise, intensive monitoring, anticoagulation management, and carefully defined patient-selection criteria.

How Critical-Care Practice Is Transforming ECMO Delivery

ECMO practice is evolving from a rescue-only intervention toward a more coordinated component of advanced critical-care pathways. Earlier referral, mobile retrieval programs, simulation-based training, standardized protocols, multidisciplinary decision-making, and structured weaning practices are improving the consistency of care. At the same time, complications including bleeding, thrombosis, infection, neurological injury, limb ischemia, and circuit failure continue to require rigorous surveillance and quality improvement.

Artificial Intelligence Is Strengthening ECMO Monitoring and Decision Support

Artificial intelligence can enhance ECMO care by integrating circuit data, laboratory results, imaging, hemodynamics, and patient records to identify deterioration and support timely clinical review. Potential applications include detecting abnormal pressure patterns, anticipating oxygenator dysfunction, optimizing ventilator and pump settings, and supporting weaning assessments. Reliable deployment depends on clinically validated models, representative datasets, explainable outputs, cybersecurity, interoperability, and clinician oversight; AI should augment rather than replace specialist judgment.

Regional Insights: Uneven Access and Specialized-Center Concentration

North America has extensive access to tertiary hospitals, established ECMO programs, and referral networks, while Canada and the United States continue to emphasize registry-based quality improvement and specialized training. Europe combines mature programs with cross-border referral and guideline development, although access varies across countries. Asia-Pacific includes highly developed systems in Australia, Japan, and South Korea alongside rapidly expanding capabilities in China and India. Latin America is strengthening advanced critical-care capacity but faces equipment, training, and referral constraints. The Middle East is investing in tertiary hospitals and regional centers, with access concentrated in more resourced health systems. Africa remains characterized by limited program availability, workforce shortages, infrastructure constraints, and the need for carefully prioritized referral and training models.

Group Insights: Alliances and Economic Blocs Shape Capability Building

ASEAN countries show varied ECMO readiness, with differences in tertiary-care capacity, financing, training, and referral coordination. BRICS members span mature, developing, and unevenly distributed capabilities, making knowledge exchange and workforce development important priorities. European Union systems benefit from shared clinical collaboration and professional networks, although national reimbursement and capacity differ. G7 countries generally possess strong critical-care infrastructure and research ecosystems, while NATO members may also draw on established emergency-response and medical logistics frameworks. GCC states are building advanced hospital capacity and specialist services, but access remains concentrated in major urban centers and referral hubs.

Country Insights: Diverse Models of ECMO Readiness

Australia combines specialized critical-care expertise with geographically important retrieval and referral capabilities. Brazil and Mexico are expanding advanced-care access while managing regional disparities and resource constraints. Canada and the United States have broad specialist infrastructure, established referral pathways, and substantial clinical experience. China and India are developing capacity across large and diverse health systems, with access varying significantly by location and institution. France, Germany, Italy, Spain, and the United Kingdom benefit from mature tertiary-care networks, though organization, reimbursement, and regional availability differ. Japan and South Korea maintain sophisticated hospital systems and specialist programs. Russia's capabilities are concentrated in major centers, with access and supply conditions varying across regions.

Priorities for Leaders: Build Reliable, Equitable ECMO Pathways

Industry leaders should prioritize interoperable circuit and monitoring systems, clinician-centered analytics, and evidence-based protocols for initiation, anticoagulation, transport, complication management, and decannulation. Partnerships with hospitals and professional societies can support simulation training, credentialing, registries, and post-market safety surveillance. Manufacturers and providers should design for maintainability, staff usability, cybersecurity, and constrained-resource settings. Health systems should strengthen referral networks, define regional ECMO hubs, evaluate outcomes transparently, and align investment with population need rather than concentrating capability without coordinated access.

Research Methodology: Evidence-Based Assessment of ECMO Therapy

This executive summary uses a structured qualitative assessment of ECMO therapy, including clinical practice patterns, care-delivery requirements, technology developments, regional health-system characteristics, and country-level infrastructure considerations. Findings are framed around documented clinical and operational realities rather than market estimates. The analysis distinguishes established applications from emerging opportunities, avoids unsupported numerical claims, and recognizes that access, outcomes, and readiness can vary substantially between institutions within the same geography.

Conclusion: Sustainable Excellence Requires Networks, Skills, and Governance

ECMO remains a high-complexity intervention whose value depends on timely patient selection, experienced teams, dependable equipment, and coordinated longitudinal care. The next phase of development will be shaped by regional network design, workforce development, interoperability, safety governance, and responsible use of AI. Progress will be strongest where health systems combine specialized expertise with equitable referral pathways, transparent quality measurement, and continuous learning.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Extracorporeal Membrane Oxygenation Therapy Market, by Type

• 7.1. Introduction
• 7.2. Venoarterial
• 7.3. Venovenous

8. Extracorporeal Membrane Oxygenation Therapy Market, by Product

• 8.1. Introduction
• 8.2. Accessories
• 8.3. Cannula
• 8.4. Oxygenator
• 8.5. Pump
• 8.6. Tubing

9. Extracorporeal Membrane Oxygenation Therapy Market, by Patient Age

• 9.1. Introduction
• 9.2. Adult
• 9.3. Neonatal
• 9.4. Pediatric

10. Extracorporeal Membrane Oxygenation Therapy Market, by Hospital Type

• 10.1. Introduction
• 10.2. Cardiac Care Centers
• 10.3. Pediatric And Neonatal Care Hospitals
  • 10.3.1. Neonatal Care Hospitals
  • 10.3.2. Pediatric Care Hospitals
• 10.4. Tertiary Care Hospitals

11. Extracorporeal Membrane Oxygenation Therapy Market, by Application

• 11.1. Introduction
• 11.2. Cardiac
• 11.3. Extracorporeal Cardiopulmonary Resuscitation
• 11.4. Respiratory

12. Extracorporeal Membrane Oxygenation Therapy Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Extracorporeal Membrane Oxygenation Therapy Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Extracorporeal Membrane Oxygenation Therapy Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Abiomed, Inc.
• 16.3. ALung Technologies, Inc.
• 16.4. Andocor N.V.
• 16.5. Braile Biomedica Industria e Comercio S.A.
• 16.6. Breethe, Inc.
• 16.7. Chalice Medical Ltd.
• 16.8. EUROSETS S.r.l.
• 16.9. Fresenius Medical Care AG & Co. KGaA
• 16.10. Getinge AB
• 16.11. Hemovent GmbH
• 16.12. LivaNova PLC
• 16.13. Medtronic plc
• 16.14. MicroPort Scientific Corporation
• 16.15. Nipro Corporation
• 16.16. OriGen Biomedical, Inc.
• 16.17. Senko Medical Instrument Manufacturing Co., Ltd.
• 16.18. Spectrum Medical Limited
• 16.19. Terumo Corporation
• 16.20. Xenios AG

17. Key Experts